TuHURA Biosciences' (HURA) Buy Rating Reiterated at HC Wainwright

Key Points

• HC Wainwright reiterated a “Buy” rating on TuHURA Biosciences and maintained a $10 price target, implying approximately 389% upside from the stock’s $2.05 price.
• Analyst sentiment is generally positive: five analysts rate HURA a Buy and one rates it a Sell, resulting in a consensus “Moderate Buy” rating and a $9 average target price.
• TuHURA reported a quarterly loss of $0.14 per share, slightly better than the $0.15 consensus estimate. The clinical-stage biotech is developing cancer immunotherapies, including its lead candidate IFx-2.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $10.00 target price on the stock. HC Wainwright's price target points to a potential upside of 389.00% from the stock's current price.

A number of other research firms also recently weighed in on HURA. Weiss Ratings restated a "sell (e+)" rating on shares of TuHURA Biosciences in a research report on Thursday, October 15th. Citizens Jmp reissued a "market outperform" rating and set a $9.00 price target on shares of TuHURA Biosciences in a research note on Tuesday, August 18th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $9.00.

TuHURA Biosciences Price Performance

NASDAQ HURA traded up $0.01 during trading hours on Tuesday, reaching $2.05. 294,319 shares of the stock traded hands, compared to its average volume of 875,923. The stock has a 50 day simple moving average of $2.04 and a two-hundred day simple moving average of $1.93. TuHURA Biosciences has a 1 year low of $0.41 and a 1 year high of $3.43. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.18 and a quick ratio of 0.18. The company has a market cap of $130.33 million, a price-to-earnings ratio of -3.79 and a beta of -0.21.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. On average, analysts predict that TuHURA Biosciences will post -0.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of HURA. Squarepoint Ops LLC bought a new position in shares of TuHURA Biosciences during the second quarter valued at about $81,000. HighTower Advisors LLC grew its position in TuHURA Biosciences by 42.5% during the 2nd quarter. HighTower Advisors LLC now owns 30,151 shares of the company's stock worth $71,000 after acquiring an additional 8,999 shares during the last quarter. Two Sigma Securities LLC bought a new position in TuHURA Biosciences during the 2nd quarter worth approximately $33,000. Hsbc Holdings PLC bought a new position in TuHURA Biosciences during the 2nd quarter worth approximately $69,000. Finally, Jefferies Financial Group Inc. bought a new position in TuHURA Biosciences during the 2nd quarter worth approximately $98,000. 0.62% of the stock is owned by institutional investors.

About TuHURA Biosciences

TuHURA Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company's research is directed toward treatments intended to address mechanisms that enable tumors to evade the immune system and resist existing cancer therapies.

TuHURA's lead product candidate, IFx-2, is an investigational cancer immunotherapy designed for intratumoral administration. The program is intended to stimulate a broader anti-tumor immune response and potentially improve the effectiveness of immune checkpoint inhibitors and other established treatments.